Jan Tijssen

Showing 1-12 of 12 articles

Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial

Kraak R, Tijssen R, van Dongen I, Elias J, Hofma S, van der Schaaf R, Arkenbout E, Weevers A, Tijssen J, Piek J, de Winter R, Henriques J, Wykrzykowska J

December 4, 2020 | 10.4244/EIJ-D-18-00884

Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial

Takahashi K, Chichareon P, Modolo R, Kogame N, Chang C, Tomaniak M, Moschovitis A, Curzen N, Haude M, Jung W, Holmvang L, Garg S, Tijssen J, Wykrzykowska J, de Winter R, Hamm C, Steg P, Stoll H, Onuma Y, Valgimigli M, Vranckx P, Windecker S, Serruys PW

October 23, 2020 | 10.4244/EIJ-D-19-00498

Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomised clinical trial

Smits P, Chang C, Chevalier B, West N, Gori T, Barbato E, Tarantini G, Kocka V, Achenbach S, Dudek D, Escaned J, Wlodarczak A, Abdel-Wahab M, Esposito G, Tijssen J, Morice M, Onuma Y, van Geuns R

October 23, 2020 | 10.4244/EIJ-D-19-01079

Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial

Tomaniak M, Chichareon P, Modolo R, Takahashi K, Chang C, Kogame N, Spitzer E, Buszman P, van Geuns R, Valkov V, Steinwender C, Geisler T, Prokopczuk J, Sabaté M, Zmudka K, Rademaker-Havinga T, Tijssen J, Jüni P, Hamm C, Steg P, Onuma Y, Vranckx P, Valgimigli M, Windecker S, Baber U, Anderson R, Dominici M, Serruys PW

April 3, 2020 | 10.4244/EIJ-D-19-00699

Coronary interventions

Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial

Serruys PW, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang C, Spitzer E, Walsh S, Adlam D, Hildick-Smith D, Édes I, van de Harst P, Krackhardt F, Tijssen J, Rademaker-Havinga T, Garg S, Steg P, Hamm C, Jüni P, Vranckx P, Onuma Y, Verheugt F

December 20, 2019 | 10.4244/EIJ-D-19-00202

Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial

Kerkmeijer L, Tijssen RY, Hofma S, van der Schaaf R, Arkenbout K, Kraak R, Weevers A, Piek J, de Winter R, Tijssen J, Henriques J, Wykrzykowska J, Ijsselmuiden A, Kauer F, Beijk M, Vis M, Koch K

September 20, 2019 | 10.4244/EIJ-D-19-00325

Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI

Tijssen RY, Kraak R, Hofma S, van der Schaaf R, Arkenbout E, Weevers A, Elias J, van Dongen I, Koch K, Baan Jr J, Vis M, de Winter R, Piek J, Tijssen J, Henriques J, Wykrzykowska J

July 20, 2018 | 10.4244/EIJ-D-18-00335

Coronary interventions

Implantation techniques (predilatation, sizing, and post-dilatation) and the incidence of scaffold thrombosis and revascularisation in lesions treated with an everolimus-eluting bioresorbable vascular scaffold: insights from the AIDA trial

Tijssen RY, Kraak R, Elias J, van Dongen I, Kalkman D, Nassif M, Sotomi Y, Asano T, Katagiri Y, Collet C, Piek J, Henriques J, de Winter R, Tijssen J, Onuma Y, Serruys PW, Wykrzykowska J

July 20, 2018 | 10.4244/EIJ-D-17-01152

Transcatheter aortic valve implantation for mixed versus pure stenotic aortic valve disease

Abdelghani M, Cavalcante R, Miyazaki Y, de Winter R, Tijssen J, Sarmento-Leite R, Mangione J, Abizaid A, Lemos P, Serruys PW, de Brito Jr F

November 20, 2017 | 10.4244/EIJ-D-17-00328

Coronary interventions

Optical coherence tomography findings: insights from the “randomised multicentre trial investigating angiographic outcomes of hybrid sirolimus-eluting stents with biodegradable polymer compared with everolimus-eluting stents with durable polymer in chronic total occlusions” (PRISON IV) trial

Teeuwen K, Spoormans E, Bennett J, Dubois C, Desmet W, Ughi G, Belmans A, Kelder J, Tijssen J, Agostoni P, Suttorp MJ, Adrianssens T

August 4, 2017 | 10.4244/EIJ-D-17-00261

Coronary interventions

Microvascular dysfunction following ST-elevation myocardial infarction and its recovery over time

Hassell M, Bax M, van Lavieren M, Nijveldt R, Hirsch A, Robbers L, Marques K, Tijssen J, Zijlstra F, van Rossum A, Delewi R, Piek J

August 4, 2017 | 10.4244/EIJ-D-16-00818

Coronary interventions

Hierarchical testing of composite endpoints: applying the win ratio to percutaneous coronary intervention versus coronary artery bypass grafting in the SYNTAX trial

Milojevic M, Head S, Andrinopoulou E, Serruys PW, Mohr F, Tijssen J, Kappetein A

May 15, 2017 | 10.4244/EIJ-D-16-00745

1

Latest news

State-of-the-Art on Coronary Physiology; a Mini Focus on Biostatistics; Post-TAVI Aortic Manipulation; Minimally Invasive Ventricular Reconstruction after MI

Don't miss the next #EIJCardioChat!

IVUS-guided stenting in VIV-TAVI

This Week's JAA's: Deep Learning Model to Detect AMI, Mortality After Bleeding vs MI in CAD Patients...

New update: EXAMINATION 10 years, BIONYX 2 years, SAFE A, MASH and more

(Thanks to the support of Biotronik)

Optimising Physiological Endpoints of Percutaneous Coronary Intervention

Reducing refractory angina

Ranil de Silva et al.

Discover EuroIntervention's New Author Centre

Valvular disease